Skip to main content

Table 1 Baseline characteristics of the enrolled study population. Normally distributed quantitative data are expressed as means±standard deviation. Non-normally distributed quantitative data are expressed as medians (IQR)

From: Prognostic factors for ARDS: clinical, physiological and atypical immunodeficiency

Variables

Acute respiratory distress syndrome

  

∆P-value

Total

Mild

Moderate

Severe

 

Number

201

31

61

109

 

Age,years

54.24 ± 16.35

55.38 ± 15.60

52.43±

54.93 ± 16.03

0.579

Sex,male/female,n

130/71

19:12

40/21

71/38

0.415

BMI,kg/m2

23.90 ± 3.82

24.22 ± 3.93

23.83 ± 4.05

23.90 ± 3.82

0.896

Cause of ARDS

 Pneumonia

125

19

37

69

 

 Non-pulmonary spesis

38

6

15

17

 

 Pancreatitis

15

4

7

4

 

 Trauma

7

0

0

7

 

 Aspiration

2

0

0

2

 

 Others

14

2

2

10

 

APACHE II score

14.19(7.69 to 31.00)

12.74(7.69 to 24.37)

14.52 (9.86 to 27.69)

14.34 (9.68 to 31.00)*

0.016

SOFA score

4.98(4.65 to 5.30)

4.59(3.97 to 5.20)

5.11 (4.71 to 5.53)

5.26 (4.89 to 5.63)

0.027

PaO2/FiO2,mmHg

123 (112 to 134)

280 (267 to 294)

140 (132 to 146)*

69 (65 to 72)* #

0.000

CRP,mg/L

129.82 (129.82 to 169.91)

110.09 (76.59 to 143.59)

163.90 (138.67 to 189.14)*

203.33 (115.97 to 290.68)*

0.011

PCT,ng/ml

12.20 (8.12 to 16.29)

9.37 (5.45 to 13.30)

10.15 (1.51 to 18.80)

17.05 (7.58 to 27.73)*

0.175

Albumin,g/L

27.67 ± 5.82

27.13 ± 3.17

27.07 ± 6.05

28.10 ± 6.05*

0.759

Hemoglobin,g/L

107.67 ± 28.32

104.04 ± 23.76

107.29 ± 28.05

108.82 ± 29.73

0.759

Leukocytes,109/L

11.33(10.12 to 12.54)

10.98 (8.67 to 13.28)

10.91 (9.62 to 12.22)

13.65 (8.65 to 18.64)

0.298

Lymphocytes,109/L

1.10 (0.95 to 1.26)

1.28 (0.86 to 1.75)

1.10 (8.67 to 13.28)

1.07 (0.87 to 1.27)*

0.025

Neutrophils,109/L

10.78 (8.38 to 13.18)

8.35 (6.91 to 9.78)

11.66 (7.59 to 15.74)

13.03 (7.31 to 18.76)

0.371

Lymphocyte/Neutrophil ratio

0.19 ± 0.03

0.35 ± 0.23

0.17 ± 0.03*

0.15 ± 0.02*

0.001

Virus infection,n,%

23(11.44%)

1(3.23%)

10(16.39%)

12(11.0%)

 

28-day mortality,n,%

103(51.24%)

13(41.94%)

31(50.82%)

59(54.13%)

 

100-day mortality,n,%

121(60.20%)

15(48.39%)

37(60.66%)

69(63.30%)

 

Immunoglobulin

     

IgG,g/L

10.87 ± 1.86

11.71 ± 4.96

10.82 ± 1.94

10.59 ± 5.36

0.095

IgA,g/L

1.98 ± 0.24

1.92 ± 1.09

1.85 ± 0.72

2.11 ± 1.40

0.270

IgM,g/L

1.05 ± 0.86

1.32 ± 1.18

1.02 ± 0.92

1.00 ± 0.72

0.598

IgE,ng/mL

620.36 ± 145.11

1426.20 ± 119.89

640.55 ± 32.45

356.87 ± 78.73*

0.025

Complement components

 C3

5.62 ± 1.78

12.27 ± 1.83

7.13 ± 3.14

0.84 ± 0.33*

0.186

 C4

1.33 ± 0.58

0.25 ± 0.13

0.24 ± 0.11

2.25 ± 0.95*

0.663

T-lymphocytes subsets

 CD3+ cells,%

62.75 ± 15.29

71.00 ± 13.78

63.35 ± 12.44

60.62 ± 17.11

0.229

 CD4+ cells,%

35.15 ± 15.48

36.40 ± 13.69

34.10 ± 11.14

35.66 ± 8.47

0.951

 CD4+ cells count (PCS/ul)

383.20 ± 67.18

176.50 ± 67.18

383.67 ± 94.79

434.08 ± 78.66

0.708

 CD8+ cells,%

27.33 ± 13.46

34.33 ± 6.37

25.60 ± 11.59

26.92 ± 14.01

0.275

 CD8+ cells count (PCS/ul)

212.33 ± 64.30

134.00 ± 30.63

286.67 ± 51.72

178.91 ± 70.96

0.409

 CD4+/CD8+ ratio

1.95 ± 0.26

1.29 ± 0.23

1.91 ± 0.93

2.14 ± 0.48

0.623

B-lymphocytes

 B-lymphocytes,%

30.25 ± 17.28

18.00 ± 3.24

26.20 ± 7.81

33.36 ± 7.81

0.598

 B-lymphocytes cell count (PCS/μl)

301.05 ± 73.77

69.01 ± 8.89

413.20 ± 41.42

271.18 ± 78.37

0.665

NK cell

 NK cells,%

8.76 ± 5.91

17.00 ± 4.41

9.40 ± 0.81

7.73 ± 4.58

0.331

 NK cell count (PCS/ul)

68.77 ± 46.46

68.20 ± 7.66

82.60 ± 14.82

62.55 ± 15.15

0.751

  1. Qualitative data are presented as numbers (%). ∆P-value for the three groups (mild, moderate, and severe ARDS groups); *P < 0.05 versus mild ARDS; #P < 0.05 versus moderate ARDS. BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation SOFA Sequential Organ Failure Assessment, CRP C-reactive protein, PCT procalcitonin